Multiple Sclerosis patients need more vitamin D to get same blood level response

Multiple sclerosis patients have a diminished serologic response to vitamin D supplementation compared to healthy controls

Mult Scler August 18, 2015 1352458515600248

1. Gave 5,000 IU of vitamin D daily to two groups for 3 months There was a 6.7 ng less response in the MS group 1. Possible reasons - by Vitamin D Life1. MS, like many other diseases, consumes vitamin D1. MS patients did not get outdoors as much (less vitamin D from the sun)* (this was not mentioned in the abstract)1. MSers have genes which deminish the VitaminD efficiency in the body1. MSers have less Magnesium (just a guess)1. Drugs being taken by MSers reduce vitamin D See also Vitamin D Life* Overview MS and vitamin D* Autistics have half of the response to Vitamin D – RCT Oct 2018* Response to Vitamin D supplementation – July 2015* Reasons for low response to vitamin D by Vitamin D Life* Drugs Deplete Magnesium* Gene differences can result in 14 ng difference in vitamin D levels– Feb 2014* Category: Drug interactions with Vitamin D has ** items * * 200 IU needed to increase vitamin D levels by 1 ng (not 100 IU) – summary of 25 studies – Feb 2014 which has the following chartNote: 1 vertical division on chart = 20 nmol, this study found only a 17 nmol difference - with a wide varianceThe articles in both MS and Genetics are: {category}

📄 Download the PDF from Vitamin D Life

Pavan Bhargava, Department of Neurology, Johns Hopkins University, Baltimore, MD, USA

Sonya U Steele, Department of Neurology, Johns Hopkins University, Baltimore, MD, USA

Emmanuelle Waubant, Department of Neurology, University of California San Francisco, San Francisco, CA, USA

Nisha R Revirajan, Department of Neurology, University of California San Francisco, San Francisco, CA, USA

Jacqueline Marcus, Department of Neurology, University of California San Francisco, San Francisco, CA, USA

Marieme Dembele, Department of Neurology, Johns Hopkins University, Baltimore, MD, USA

Sandra D Cassard, Department of Neurology, Johns Hopkins University, Baltimore, MD, USA

Bruce W Hollis, Department of Pediatrics, Medical University of South Carolina, Charleston, SC, USA

Ciprian Crainiceanu, Department of Biostatistics, Johns Hopkins School of Public Health, Baltimore, MD, USA

Ellen M. Mowry, Department of Neurology, Johns Hopkins University, Baltimore, MD, USA

Department of Neurology, Johns Hopkins University, 600 N Wolfe Street, Pathology 627, Baltimore, MD 21287, USA. [email protected]

Response to 5,000 IU daily

Background: Vitamin D insufficiency is a risk factor for multiple sclerosis (MS), and patients do not always show the expected response to vitamin D supplementation.

Objective: We aimed to determine if vitamin D supplementation leads to a similar increase in serum 25-hydroxyvitamin-D (25(OH)D) levels in patients with MS and healthy controls (HCs).

Methods: Participants in this open-label study were female, white, aged 18–60 years, had 25(OH)D levels ⩽ 75 nmol/l at screening, and had relapsing–remitting MS (RRMS) or were HCs. Participants received 5000 IU/day of vitamin D3 for 90 days. Utilizing generalized estimating equations we examined the relationship between the primary outcome (serum 25(OH)D level) and the primary (MS versus HC status) and secondary predictors.

Results: For this study 27 MS patients and 30 HCs were enrolled. There was no significant difference in baseline 25(OH)D level or demographics except for higher body mass index (BMI) in the MS group (25.3 vs. 23.6 kg/m2, p=0.035). In total, 24 MS subjects and 29 HCs completed the study. In a multivariate model accounting for

• BMI,

• medication adherence, and

• oral contraceptive use,

MS patients had a 16.7 nmol/l (95%CI: 4.2, 29.2, p=0.008) lower increase in 25(OH)D levels compared with HCs.

Conclusions: Patients with MS had a lower increase in 25(OH)D levels with supplementation, even after accounting for putative confounders.